Key Takeaways:
- Belgium-based ExeVir Bio has raised €1.6 million in grant funding.
- The round was led by Flanders Innovation and Entrepreneurship (VLAIO).
- ExeVir Bio develops single-domain antibody-based therapies to combat viral infections.
- This funding pushes the company’s total capital to a whopping €68.6 million.
Belgium-based startup, ExeVir Bio, has recently confirmed a triumphant fundraising round, amassing €1.6 million. The funding was in the form of a grant, predominantly bankrolled by Flanders Innovation and Entrepreneurship (VLAIO).
ExeVir Bio, located in Zwijnaarde, Oost-Vlaanderen, Belgium, is doing groundbreaking work in the biotechnology, health care, life science, and therapeutics industry. Its focus is on the development of single-domain antibody-based therapies, a crucial player in the ongoing fight against viral infections. With the recent grant, the startup has taken another significant stride towards fulfilling its innovative therapeutic vision.
The company’s Crunchbase profile reveals that this is the third funding round for ExeVir Bio. The previous rounds successfully accumulated an impressive total of €68.6 million, helping to push forward the firm’s research and development efforts.
The grant funding comes in a timely fashion as the world continues to grapple with various viral threats. The new funds will likely enable ExeVir Bio to accelerate its research and increase the capacity for clinical trials, potentially bringing their solutions to patients much sooner.
The lead investor for this round, Flanders Innovation and Entrepreneurship (VLAIO), is no stranger to backing groundbreaking biotech endeavors. This investment in ExeVir Bio underscores their confidence in the company’s robust scientific approach and their potential to make a significant impact on global healthcare.
As ExeVir Bio continues to pioneer advancements in viral therapeutics, the tech and healthcare communities will certainly be keeping a close watch. This recent fundraise brings promise and excitement for what the future of viral infection treatment might look like, with ExeVir Bio leading the charge.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
